IceCure Medical Ltd. has reported its financial results for the first quarter ending March 31, 2025. The company's revenue from sales of ProSense® systems and disposable probes was $725,000, reflecting a 2% decrease from $743,000 in the same period in 2024. This reduction was mainly due to a decline in sales in Asia, although this was partially offset by increases in Europe and North America. Gross profit for the quarter was $218,000, down from $269,000 in the previous year, with a gross margin of 30% compared to 36% in 2024. This decrease was attributed to the slight decline in revenue and changes in product mix. Research and development expenses decreased by 15% to $1.664 million, primarily due to reduced development costs for the XSense™ System following its FDA authorization in June 2024, along with lower clinical and regulatory costs after concluding the ICE3 study in March 2024. Conversely, sales and marketing expenses rose by 24% to $1.289 million as the company ramped up global marketing efforts to support growing sales. IceCure Medical has also delivered a proposed post-market study plan to the U.S. FDA ahead of its marketing authorization decision for ProSense® in women aged 70+ with early-stage low-risk breast cancer. The company continues to witness rising interest for ProSense® in North America. Looking forward, the company does not anticipate a material change in revenues until after the FDA's marketing authorization decision.